A new academic analysis argues that moving cannabis from Schedule I to Schedule III under the Controlled Substances Act would be a historic step—but only a “transitional” one that needs to be followed by much bigger reforms.
Researchers say rescheduling could make a real difference in certain areas. For example, it would likely expand scientific research, since the current Schedule I classification places heavy restrictions on studying cannabis. It could also make it easier for companies to pursue FDA-approved cannabis-based medicines.
But the analysis stresses that rescheduling alone would not legalize marijuana federally and wouldn’t resolve the major conflicts between federal law and the dozens of states that already allow medical or adult-use cannabis.
The researchers say several additional reforms would still be needed, including:
Banking reform, so cannabis businesses can access normal financial services instead of operating largely in cash.
Commerce rules, to clarify how cannabis could move across state lines in a federally regulated system.
Criminal justice reforms, including policies that address past cannabis convictions and equity issues created during prohibition.
Another concern raised in the analysis is that rescheduling alone could actually accelerate consolidation in the industry, potentially giving larger corporations an advantage if broader protections and regulations aren’t put in place.
In other words, rescheduling would be a big moment for federal cannabis policy—but it wouldn’t magically solve the industry’s biggest challenges overnight.
According to the researchers, it would simply mark the beginning of the next phase of reform, not the end of the road.
Dabbin-Dad Newsroom
